论文部分内容阅读
目的比较瑞舒伐他汀剂量加倍与联用普罗布考对冠心病合并高胆固醇血症患者的疗效。方法在2012年1月至2013年12月在长海医院心内科就诊的冠心病患者中,选取经瑞舒伐他汀10mg、每晚1次治疗3个月以上,低密度脂蛋白胆固醇(LDL-C)仍不能达标者,将其随机分为他汀剂量加倍组(瑞舒伐他汀片20mg、每晚1次)和联合治疗组(瑞舒伐他汀片10mg、每晚1次+普罗布考片250mg、每天2次),每组各34例,治疗3个月。比较两组患者治疗前和治疗后外周血脂水平的变化以及不良反应发生率。结果治疗前两组患者一般情况、血脂水平差异无统计学意义(P>0.05)。治疗后3个月,两组患者总胆固醇(TC)、LDL-C均明显下降(P<0.05);联合治疗组三酰甘油(TG)明显下降(P<0.05);他汀加倍组、联合治疗组高密度脂蛋白胆固醇(HDL-C)分别显示升高和下降的趋势,但均未达到统计学差异(P>0.05)。与他汀加倍组相比,联合治疗组TC、LDL-C降得更低(P<0.05),LDL-C达标率更高(P<0.05),但HDL-C明显降低(P<0.05)。两组患者不良反应发生率比较,联合治疗组明显低于他汀加倍组(P<0.05)。结论对于冠心病合并高胆固醇血症患者,瑞舒伐他汀与普罗布考联合使用优于瑞舒伐他汀剂量加倍的疗效,且具有更高的安全性。
Objective To compare the effect of rosuvastatin dose doubling with probucol on coronary heart disease complicated with hypercholesterolemia. Methods From January 2012 to December 2013, 10 mg of rosuvastatin and more than 3 months of treatment were taken in patients with coronary heart disease in Department of Cardiology, Changhai Hospital. Low-density lipoprotein cholesterol (LDL-C ) Were still unable to meet the standard, they were randomly divided into statin dosing group (rosuvastatin tablets 20mg, 1 night) and the combination group (rosuvastatin tablets 10mg, 1 night + probucol 250mg , 2 times a day), 34 cases in each group, treatment for 3 months. The changes of peripheral blood lipid levels and the incidence of adverse reactions in both groups before and after treatment were compared. Results Before treatment, there was no significant difference in the general situation and blood lipid levels between the two groups (P> 0.05). At 3 months after treatment, total cholesterol (TC) and LDL-C in both groups were significantly decreased (P <0.05); triglyceride (TG) in combination therapy group decreased significantly Group HDL-C showed the trend of rising and falling, but did not reach the statistical difference (P> 0.05). Compared with the statin doubling group, TC and LDL-C in combination therapy group were lower (P <0.05), LDL-C compliance rate was higher (P <0.05), but HDL-C was significantly lower (P <0.05). Two groups of patients with adverse reactions compared with the combination therapy group was significantly lower than the statin doubling group (P <0.05). Conclusions The combination of rosuvastatin and probucol in patients with coronary heart disease complicated with hypercholesterolemia is superior to rosuvastatin dose doubling and has higher safety.